August 13, 2021 7:42am
The real question is: are there investors or hedge and electronic trading buying i.e., “flippers”
Pre-open indications: 1 BUYs; 3 SELLs: 2 SELLs into Strength; 1 Maintain SELL
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
There is no breadline for fact and numbers-based share pricing intelligence!
Dow futures are UP +0.13% (+47 points), S&P futures are UP +0.04% (+2 point) and NASDAQ futures are DOWN -0.03% (-5 points)
Stock futures are mixed, barely higher and weak in Friday’s pre-open,
European markets were flatlining,
Asia-Pacific markets retreated, with South Korea’s Kospi leading losses
Data Docket: UN of Michigan’s first reading of consumer sentiment for August
Henry’omics:
The week has digested a mixed bag of economic data
This week so far, Dow popped +0.8% and the S&P 500 ascended +0.6% although the Nasdaq underperformed -0.1%.
Stocks have rising to records, which brings back my retort – BYE.
Thursday’s evening’s recap: “the cell and gene therapy sector flips positive at mid-day. Below the surface, the oversold battles the overbought; there are just some things that can be counted upon to occur and they are what in these markets?” … https://www.regmedinvestors.com/articles/12047
- The Nasdaq closed UP +51.13 points (+0.35%);
- The IBB closed up +0.83% and XBI closed up +0.90%;
- Sector volume INCREASED with 1 of the 19-upside having higher than the 3-month average volume with very LOW volume of 3 of 13-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.47 points or -2.93% at 15.59;
- Thursday’s percentage (%) of the 19-upside were +0.35% (VSTM) to +6.09% (MDXG) while the 13-downside -0.03% (RARE) to -5.80% (GBT);
Q3/21:
- August: 5 positive and 4 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?
Biostage (BSTG) closed flat again on Thursday after Wednesday with 50 shares traded following Tuesday with 4 shares traded, Monday’s down -$0.05 with 1060 shares traded, Friday’s +$0.05 on Friday with 709 shares traded and last Thursday with 5 shares traded.
Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Pre-open Indications: a frenetic market with resulting sector bumps and dumps
SELL into Strength:
CRISPR Therapeutics (CRSP) closed up +$1.70 with a positive +$0.62 or +0.46% aftermarket indication,
BioLife Solutions (BLFS) closed up +$1.93 with a positive +1.31 or +2.73% aftermarket indication;
SELL:
bluebird bio (BLUE) closed down -$0.23 with a negative -$0.03 or -0.16% aftermarket indication,
Editas Medicine (EDIT) closed up =$0.96 with a negative -0.89 or -1.36% pre-market indication
Mesoblast (MESO) closed up +0.15 with a negative -$0.37 or -4.86% aftermarket indication,
BUY:
Applied Genetic Technologies (AGTC) closed up +0.07 and has a positive +$0.02 or +0.54% pre-market indication,
The BOTTOM LINE: The recent bout of pricing inconsistency in the cell and gene therapy sector could be chalked up to a LACK of any … impression of any kind in my 35 covered companies in this Q2 earnings season.
Although three (3) net incomes are a bright light …
I’m still skittish about today, Friday after experiencing a NERVOUS all week
The cell and gene therapy sector has experience dramatic upside move and downside putting a real edge on share pricing as earnings continued to guide sector sentiment …
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC), Biostage (BSTG), Mesoblast (MESO), Pluristem (PSTI) and Solid Biosciences (SLDB), Pluristem (PSTI), ReNeuron (RENE.L)
Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
Risk is no doubt increasing as we head into the troublesome August and September months
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
